Loss of PTEN Expression as a Prognostic Marker for Tongue Cancer

Janet I. Lee(Baylor College of Medicine), Li Mao(Nanjing University of Chinese Medicine), Khaled A. Hassan(The University of Texas MD Anderson Cancer Center), Diane D. Liu(The University of Texas MD Anderson Cancer Center), Adel K. El‐Naggar(The University of Texas MD Anderson Cancer Center), Jean‐Charles Soria(Inserm), Waun Ki Hong(Shenzhen Nanshan Center for Chronic Disease Control), Ximing Tang(The University of Texas MD Anderson Cancer Center)
Archives of Otolaryngology - Head and Neck Surgery
December 1, 2001
10.1001/archotol.127.12.1441
Cited by 126

Related Papers

Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Rociletinib in <i>EGFR</i>-Mutated Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2015|664
Frequency of homozygous deletion at p16/CDKN2 in primary human tumours
|Nature Genetics|1995|646
Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer
|Nature Medicine|2022|637
Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study
|The Lancet Oncology|2018|614